Tamoghna Ghosh

Employment

Employment history is unavailable.

Education

• All India Institute of Medical Sciences MBBS
  2017 - Present

Projects & Funding

Projects & funding information is unavailable.

Publications (16)

• P396 Utility of nasal swabs as samples for the diagnosis of Mucormycosis using molecular methods for detection
  Medical Mycology 2022 DOI: 10.1093/mmy/myac072.p396
  +Save
• Intrathecal Co-administration of Morphine Facilitated the Anti-nociceptive of Bupivacaine in a Rat Model of Acute Postoperative Pain.
  Cureus 2022 DOI: 10.7759/cureus.28385
  +Save
• A Systematic Review of Crohn's Disease Case Definitions in Administrative or Claims Databases.
  Inflammatory bowel diseases 2022 DOI: 10.1093/ibd/izac131
  +Save
• Clinical profile and in-hospital outcomes of COVID-19 among adolescents at a tertiary care hospital in India.
  Lung India : official organ of Indian Chest Society 2022 DOI: 10.4103/lungindia.lungindia_128_22
  +Save
• Utility of walk tests in progression of mild COVID-19 infection at a tertiary hospital in North India.
  Recent advances in anti-infective drug discovery 2022 DOI: 10.2174/2772434417666220630112737
  +Save
• Comparison of in-hospital COVID-19 related outcomes between COVISHIELD and COVAXIN recipients.
  Lung India : official organ of Indian Chest Society 2022 DOI: 10.4103/lungindia.lungindia_141_22
  +Save
• Impact of various hematological and biochemical parameters on mortality in coronavirus disease 2019 (COVID-19): A single-center study from North India.
  Lung India : official organ of Indian Chest Society 2022 DOI: 10.4103/lungindia.lungindia_480_21
  +Save
• Risk factors for Coronavirus disease-associated mucormycosis
  Journal of Infection 2022 DOI: 10.1016/j.jinf.2021.12.039
  +Save
• Clinical profile of small-cell lung cancer in North India: A 12-year analysis from a tertiary care center
  Lung India 2022 DOI: 10.4103/lungindia.lungindia_48_22
  +Save
• In-hospital mortality due to breakthrough COVID-19 among recipients of COVISHIELD (ChAdOx nCoV-19) and COVAXIN (BBV152)
  2021 DOI: 10.1101/2021.12.07.21267398
  +Save